Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study.
Gerotziafas GT, Zografos T, Pantos I, Lefkou E, Carlo A, Fareed J, Van Dreden P, Katritsis D. Gerotziafas GT, et al. Among authors: van dreden p. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620964590. doi: 10.1177/1076029620964590. Clin Appl Thromb Hemost. 2020. PMID: 33284037 Free PMC article. Clinical Trial.
Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
Chaari M, Ayadi I, Rousseau A, Lefkou E, Van Dreden P, Sidibe F, Ketatni H, Galea V, Khaterchi A, Bouzguenda R, Frikha M, Ghorbal L, Daoud J, Kallel C, Quinn M, Gligorov J, Lotz JP, Hatmi M, Elalamy I, Gerotziafas GT. Chaari M, et al. Among authors: van dreden p. BMC Cancer. 2014 Dec 22;14:991. doi: 10.1186/1471-2407-14-991. BMC Cancer. 2014. PMID: 25535397 Free PMC article.
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT. Syrigos K, et al. Among authors: van dreden p. Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13. Oncologist. 2018. PMID: 30104289 Free PMC article.
PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study.
Boura P, Evmorfiadis I, Rousseau A, Charpidou A, Giozos G, Van Dreden P, Syrigos K, Larsen A, Elalamy I, Gerotziafas GT. Boura P, et al. Among authors: van dreden p. Thromb Res. 2016 Apr;140 Suppl 1:S196. doi: 10.1016/S0049-3848(16)30186-4. Epub 2016 Apr 8. Thromb Res. 2016. PMID: 27161741
84 results